Suppr超能文献

解剖乳房成像衍生参数不能为前哨淋巴结淋巴闪烁显像不显影提供预测的附加信息。

Anatomical breast imaging-derived parameters do not provide incremental information in prediction of nonvisualization of sentinel lymph nodes on lymphoscintigraphy.

机构信息

Departments of Radiology and Nuclear Medicine.

Clinical Pharmacy, Amsterdam UMC, location AMC.

出版信息

Nucl Med Commun. 2022 Aug 1;43(8):877-880. doi: 10.1097/MNM.0000000000001585. Epub 2022 May 18.

Abstract

OBJECTIVE

Accurate sentinel lymph node (SLN) staging is essential for both prognosis and treatment in patients with breast cancer. However, the preoperative lymphoscintigraphy may fail to visualize the SLN. The aim of this retrospective study was to investigate whether parameters derived from anatomical breast imaging can predict SLN nonvisualization on lymphoscintigraphy.

METHODS

For this retrospective study, all data of mammography, breast MRI, and lymphoscintigraphy of SLN procedures from January 2016 to April 2021 were collected and reviewed from the Amsterdam UMC database.

RESULTS

A total of 758 breast cancer patients were included in this study. SLN nonvisualization on planar lymphoscintigraphy at 2-h postinjection (pi) was 29.7% and was reduced after a second injection to 7.5% at late lymphoscintigraphy 4-h pi. Multivariable analysis showed that age ≥ 70 years ( P = 0.019; OR, 1.82; 95% CI, 1.10-3.01), BMI ≥ 30 kg/m 2 ( P = 0.031; OR, 1.59; 95% CI, 1.04-2.43), and nonpalpable tumors ( P = 0.034; OR, 1.54; 95% CI, 1.03-2.04) were independent predictors of SLN nonvisualization. Differences in tumor size, Breast Imaging-Reporting and Data System classification, or breast density were not significantly associated with SLN nonvisualization.

CONCLUSION

This study shows that, by using a multivariable analysis, risk factors for SLN nonvisualization in breast cancer patients during preoperative lymphoscintigraphy at 2-h pi are age ≥ 70 years, BMI ≥ 30 kg/m 2 , and nonpalpable tumors. Parameters derived from mammography or breast MRI, however, are not useful to predict SLN nonvisualization on lymphoscintigraphy.

摘要

目的

准确的前哨淋巴结(SLN)分期对于乳腺癌患者的预后和治疗都至关重要。然而,术前淋巴闪烁显像术可能无法显示 SLN。本回顾性研究的目的是探讨来自解剖乳房成像的参数是否可以预测淋巴闪烁显像术上 SLN 的不可见性。

方法

本回顾性研究从阿姆斯特丹 UMC 数据库中收集并回顾了 2016 年 1 月至 2021 年 4 月期间所有的乳房 X 线摄影术、乳房 MRI 和 SLN 程序的淋巴闪烁显像术的数据。

结果

本研究共纳入 758 例乳腺癌患者。注射后 2 小时(pi)平面淋巴闪烁显像术上 SLN 不可见率为 29.7%,在延迟淋巴闪烁显像术 4 小时 pi 时,第二次注射后降低至 7.5%。多变量分析显示,年龄≥70 岁(P=0.019;OR,1.82;95%CI,1.10-3.01)、BMI≥30kg/m2(P=0.031;OR,1.59;95%CI,1.04-2.43)和不可触及的肿瘤(P=0.034;OR,1.54;95%CI,1.03-2.04)是 SLN 不可见的独立预测因素。肿瘤大小、乳腺成像报告和数据系统分类或乳腺密度的差异与 SLN 不可见性无显著相关性。

结论

本研究表明,通过多变量分析,术前淋巴闪烁显像术 2 小时 pi 时乳腺癌患者 SLN 不可见的危险因素为年龄≥70 岁、BMI≥30kg/m2和不可触及的肿瘤。然而,来自乳房 X 线摄影术或乳房 MRI 的参数对于预测淋巴闪烁显像术上 SLN 不可见性并不有用。

相似文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验